Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Unknown status
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
Brief summary: This is a phase II study to investigate the safety, preliminary efficacy and
pharmacokinetics of AD-35 tablet in patients with mild to moderate Alzheimer's Disease. This
study is to be run in China involving 21 sites. It will enroll approximately 480 patients to
ensure 240 randomized with mild to moderate Alzheimer's Disease. The treatment period is 52
weeks and total study duration per patient is approximately 57 weeks.